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BACKGROUND
Point-of-care testing of C-reactive protein (CRP) may be a way to reduce unnecessary 
use of antibiotics without harming patients who have acute exacerbations of chronic 
obstructive pulmonary disease (COPD).
METHODS
We performed a multicenter, open-label, randomized, controlled trial involving pa-
tients with a diagnosis of COPD in their primary care clinical record who consulted 
a clinician at 1 of 86 general medical practices in England and Wales for an acute 
exacerbation of COPD. The patients were assigned to receive usual care guided by 
CRP point-of-care testing (CRP-guided group) or usual care alone (usual-care group). 
The primary outcomes were patient-reported use of antibiotics for acute exacerbations 
of COPD within 4 weeks after randomization (to show superiority) and COPD-related 
health status at 2 weeks after randomization, as measured by the Clinical COPD 
Questionnaire, a 10-item scale with scores ranging from 0 (very good COPD health 
status) to 6 (extremely poor COPD health status) (to show noninferiority).
RESULTS
A total of 653 patients underwent randomization. Fewer patients in the CRP-guided 
group reported antibiotic use than in the usual-care group (57.0% vs. 77.4%; adjusted 
odds ratio, 0.31; 95% confidence interval [CI], 0.20 to 0.47). The adjusted mean differ-
ence in the total score on the Clinical COPD Questionnaire at 2 weeks was −0.19 points 
(two-sided 90% CI, −0.33 to −0.05) in favor of the CRP-guided group. The anti-
biotic prescribing decisions made by clinicians at the initial consultation were 
ascertained for all but 1 patient, and antibiotic prescriptions issued over the first 
4 weeks of follow-up were ascertained for 96.9% of the patients. A lower percent-
age of patients in the CRP-guided group than in the usual-care group received an 
antibiotic prescription at the initial consultation (47.7% vs. 69.7%, for a difference 
of 22.0 percentage points; adjusted odds ratio, 0.31; 95% CI, 0.21 to 0.45) and during 
the first 4 weeks of follow-up (59.1% vs. 79.7%, for a difference of 20.6 percentage 
points; adjusted odds ratio, 0.30; 95% CI, 0.20 to 0.46). Two patients in the usual-
care group died within 4 weeks after randomization from causes considered by the 
investigators to be unrelated to trial participation.
CONCLUSIONS
CRP-guided prescribing of antibiotics for exacerbations of COPD in primary care 
clinics resulted in a lower percentage of patients who reported antibiotic use and who 
received antibiotic prescriptions from clinicians, with no evidence of harm. (Funded 
by the National Institute for Health Research Health Technology Assessment Pro-
gram; PACE Current Controlled Trials number, ISRCTN24346473.)
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Primary care providers are respon-sible for the majority of antibiotic prescrip-tions, and the highest overall number of 
such prescriptions are issued by family physicians.1 
There is reason to believe that many of these pre-
scriptions could be avoided.2,3 Unwarranted use of 
antibiotics drives antimicrobial resistance, wastes 
resources, may cause adverse effects, negatively 
affects the microbiome of patients, and distracts 
from potentially more effective interventions.4-10 
Point-of-care tests for acute infections are being 
promoted by government organizations, the in-
dustry, and clinical guidelines to better target 
antibiotic prescribing, help contain antimicrobial 
resistance, and improve patient outcomes.11 How-
ever, most evaluations of point-of-care tests for 
acute infections have solely examined analytic 
performance; only a few trials have evaluated the 
effectiveness of such tests in improving outcomes 
in the patients for whom the tests are intended to 
be used.12-14
Chronic obstructive pulmonary disease (COPD) 
was the third leading cause of death in the United 
States in 2014,15 and 6.4% of Americans reported 
receiving a diagnosis of the condition.16 About 
2% of the adult population in the United Kingdom 
have a diagnosis of COPD in their primary care 
medical record.17,18 Each year, approximately half 
the patients living with COPD have one or more 
acute exacerbations of the disease that leads to 
treatment with oral glucocorticoids, antibiotics, 
or both or hospitalization, and a quarter have two 
or more acute exacerbations per year.19,20 More 
than 80% of these patients receive antibiotic pre-
scriptions in the United States21,22 and in Europe.23 
Although many patients who have acute exacer-
bations of COPD are helped by these treatments, 
others are not.24-26
Noninfectious factors were thought to cause 
approximately 20% of acute exacerbations of COPD 
in a hospital study.27 The guidelines of the Global 
Initiative for Chronic Obstructive Lung Disease 
recommend the use of antibiotics in moderately 
or severely ill patients with acute exacerbations 
of COPD who have increased cough and sputum 
purulence.28 Recommendations for antibiotic pre-
scribing in primary care practice are generally 
based on clinical features alone (e.g., the An-
thonisen criteria,29 which include increased dys-
pnea, increased sputum volume, and increased 
sputum purulence), but these features are sub-
jective and insufficiently accurate in predicting 
which patients can be treated safely without anti-
biotics.24
C-reactive protein (CRP), an acute-phase protein 
that can be measured accurately within minutes 
at the point of care, is a biomarker for assessing 
acute exacerbations of COPD.30,31 A randomized, 
controlled trial involving patients with acute exac-
erbations of COPD recruited from primary care 
practices showed little difference in the rate of 
clinical cure with either antibiotics or placebo 
among those who had a CRP level of less than 
40 mg per liter.32 The results of point-of care CRP 
tests may inform prescribing decisions for acute 
exacerbations of COPD, but data from pragmatic, 
randomized, controlled trials regarding the clin-
ical effectiveness of such tests are lacking. We 
aimed to determine whether a CRP point-of-care 
test used in the assessment of acute exacerbations 
of COPD in primary care can safely reduce the use 
of antibiotics among such patients.
Me thods
Trial Design and Oversight
This multicenter, open-label, randomized, con-
trolled trial was conducted from January 2015 
through September 2017 in accordance with a 
previously published protocol,33 which is available 
with the full text of this article at NEJM.org. The 
trial involved patients recruited from 86 general 
medical practices in the United Kingdom. The 
Research Ethics Committee for Wales, recognized 
by the United Kingdom Ethics Committee Author-
ity, approved the trial protocol on September 15, 
2014, as well as the inclusion of all the recruitment 
sites in the trial. Health boards and clinical com-
missioning groups of the National Health Service 
gave research and development approval to partici-
pating sites. Written informed consent was ob-
tained from all the patients by the responsible 
primary care physician or an appropriately trained 
staff member. The authors vouch for the accuracy 
and completeness of the data and for the fidelity 
of the trial to the protocol. An independent trial 
steering committee and a data monitoring and 
ethics committee provided trial oversight.
Afinion desktop devices for CRP point-of-care 
testing (Alere, now Abbott) were loaned by the 
company. The staff members at the general medi-
cal practices were trained in the use, care, and 
calibration of the devices by representatives of 
Alere (at no cost to the trial or to the practices) 
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or by members of the trial team. The company had 
no role in the design of the trial; in the accrual, 
analysis, or interpretation of the data; or in the 
preparation of the manuscript. Two participating 
practices used their own CRP test device.
Patients
Patients who were 40 years of age or older were 
eligible for inclusion if they had a diagnosis of 
COPD in their primary care clinical record and 
were presenting with an acute exacerbation of 
COPD with at least one of the Anthonisen criteria. 
A full list of inclusion and exclusion criteria is 
provided in Section 1 in the Supplementary Ap-
pendix, available at NEJM.org. The patients were 
randomly assigned in a 1:1 ratio to receive usual 
care guided by CRP point-of-care testing (CRP-
guided group) or usual care alone (usual-care 
group); the number of Anthonisen criteria present 
(one to three) was used as a minimization vari-
able, with a random element set at 80%.
Trial Procedures
Before randomization, we collected information on 
the number of days that symptoms of acute exac-
erbation of COPD were present, a patient’s medical 
history, examination findings from clinicians, a 
sputum sample (if obtainable), a throat swab, pa-
tient responses to the self-administered Clinical 
COPD Questionnaire,34 and patients’ responses to 
the European Quality of Life–5 Dimensions 5-Level 
questionnaire (EQ-5D-5L; scores range from −0.28 
to 1.00, with higher scores indicating a better state 
of health).35 Clinicians recorded their antibiotic 
prescribing and other management decisions after 
randomization on a case report form.
The patients were followed up by means of 
telephone calls at weeks 1 and 2 and by face-to-face 
consultation at week 4. At 6 months, a self-admin-
istered, standardized version of the Chronic Re-
spiratory Disease Questionnaire (CRQ-SAS)36 and 
an EQ-5D-5L were mailed to the patients, and rel-
evant data were collected from the primary care 
electronic medical records. Additional details re-
garding trial procedures are provided in Section 2 
in the Supplementary Appendix.
Trial Interventions
Clinicians were asked to perform a CRP point-of-
care test as part of their assessment of patients in 
the CRP-guided group at the initial consultation 
and at any further consultations for acute exacer-
bations of COPD over the next 4 weeks; those in 
the usual-care group did not undergo CRP test-
ing. All the participating sites were provided with 
a summary of guidance from the National Insti-
tute for Health and Care Excellence and the Global 
Initiative for Chronic Obstructive Lung Disease. 
Clinicians were provided with guidance on the 
interpretation of CRP test results emphasizing 
that decisions about antibiotic prescribing should 
be based on a comprehensive assessment of likely 
risks and benefits, given a patient’s underlying 
health status and clinical features. The guidance 
noted that for patients with a CRP level lower 
than 20 mg per liter, antibiotics are unlikely to be 
beneficial and usually should not be prescribed; 
for those with a CRP level from 20 to 40 mg per 
liter, antibiotics may be beneficial, mainly if puru-
lent sputum is present; and for those with a CRP 
level higher than 40 mg per liter, antibiotics are 
likely to be beneficial.24
Outcome Measures
We used two primary outcomes because any re-
duction in the use of antibiotics should be consid-
ered alongside any negative effect on the well-being 
of a patient.37 The first primary outcome was pa-
tient-reported antibiotic use for an acute exacerba-
tion of COPD within 4 weeks after randomization. 
The second primary outcome was COPD-related 
health status, as measured by the Clinical COPD 
Questionnaire at 2 weeks after randomization. 
The Clinical COPD Questionnaire is a 10-item scale 
with a score ranging from 0 (very good) to 6 (ex-
tremely poor). The minimal clinically important 
difference is 0.4.38 Since we would need to show 
both a reduction in antibiotic use and no worsen-
ing of COPD-related health status in order for us 
to consider the CRP point-of-care test to be ef-
fective, we designed this study to answer both 
questions.
Key secondary outcomes included the preva-
lence of potentially pathogenic and resistant patho-
gens in sputum and commensal organisms in the 
throat; other assessments of COPD-related health 
status, as measured by the Clinical COPD Ques-
tionnaire; antibiotic use for any cause during the 
first 4 weeks of follow-up; antibiotic prescribing 
during the first 4 weeks of follow-up; use of other 
treatments for COPD; adverse effects of antibiotics; 
health care utilization; health utility, as measured 
by the EQ-5D-5L; general health status, as mea-
sured by the EQ-5D visual analogue scale (scores 
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range from 0 to 100, with higher scores indicating 
better health status), and disease-specific health-
related quality of life, as measured by the CRQ-SAS 
across four domains (dyspnea, fatigue, emotional 
functioning, and mastery), with scores ranging 
from 1 to 7 and higher scores indicating better 
patient outcomes on the respective domain.
Statistical Analysis
Allowing for a loss to follow-up of 20%, we es-
timated that a sample size of 650 patients would 
provide 81 to 90% overall power to detect a be-
tween-group difference of 15 percentage points in 
the percentage of patients who used antibiotics 
for acute exacerbations of COPD during 4 weeks 
of follow-up, on the basis of an estimated 70% of 
patients with antibiotic use for acute exacerbations 
of COPD during the first 4 weeks of follow-up and 
to show that usual care with CRP-guided man-
agement did not lead to worse COPD-related health 
status (i.e., was noninferior) than usual care alone. 
Given the noninferiority research question, we 
were interested in the upper limit of the confidence 
interval of the adjusted mean difference. Therefore, 
our sample-size calculation was based on a one-
sided 95% confidence interval, which is equivalent 
to a two-sided 90% confidence interval. Additional 
details on the sample size justification are provid-
ed in Section 3 in the Supplementary Appendix.
The main analysis of clinical effectiveness was 
performed in a modified intention-to-treat popu-
lation, which included all the patients who had 
undergone randomization and had available out-
come data, regardless of protocol deviations or 
the intervention they received. Analyses of the 
primary outcomes were also performed in the full 
intention-to-treat population, which included all 
the patients who had undergone randomization, 
with the use of multiple imputation to account for 
missing observations. Additional details regard-
ing the full intention-to-treat analyses and other 
prespecified analyses are provided in Sections 6 
and 7 in the Supplementary Appendix. The primary 
analysis of antibiotic use involved a two-level lo-
gistic-regression model, with the potential corre-
lated nature of the data from the patients within 
practices taken into account. The model was ad-
justed for the number of Anthonisen criteria pres-
ent before randomization. The primary analysis of 
the total score on the Clinical COPD Questionnaire 
involved a two-level analysis of covariance, with 
patients nested within practices and adjustment 
for both the number of Anthonisen criteria present 
and total score on the Clinical COPD Question-
naire at baseline. A complier average causal effect 
(an estimate of the effect of receiving the assigned 
intervention that conforms with the randomiza-
tion scheme)39 was estimated for the primary 
outcome of total score on the Clinical COPD 
Questionnaire. Model estimates for the analysis 
of the total score on the Clinical COPD Question-
naire are presented as adjusted mean differences 
with two-sided 90% confidence intervals. In both 
the modified intention-to-treat and complier aver-
age causal effect analyses, noninferiority was con-
cluded on the basis of the upper limit of the confi-
dence interval excluding 0.3, which is slightly 
smaller (more conservative) than the previously 
published minimal clinically important difference 
of 0.4.40 Secondary outcomes were analyzed simi-
larly; however, because the estimated confidence 
intervals for our secondary outcomes have not 
been adjusted for multiple testing, inferences 
drawn from these may not be reproducible. Full 
details of the subgroup analyses are provided in 
Section 9 in the Supplementary Appendix.
R esult s
Patients
Between January 2015 and February 2017, a total 
of 653 patients from 86 general medical practices 
underwent randomization (Fig. 1). Three patients 
withdrew consent to use their data, and 1 under-
went randomization in error, which left 325 pa-
tients in the CRP-guided group and 324 in the 
usual-care group. The trial groups were well 
matched at baseline (Table 1). The microbiologic 
features of the sputum samples obtained at base-
line are provided in Figure S1 and Table S1 in the 
Supplementary Appendix.
Intervention
A total of 317 of the 325 patients (97.5%) assigned 
to the CRP-guided group received a CRP test dur-
ing the recruitment consultation, and the median 
CRP value was 6 mg per liter (interquartile range, 
5.0 to 18.5). Among these 317 patients, 241 (76.0%) 
had CRP values lower than 20 mg per liter; 38 
(12.0%) had CRP values between 20 and 40 mg 
per liter, and 38 (12.0%) had CRP values higher 
than 40 mg per liter. A total of 3 of the 324 patients 
(0.9%) assigned to the usual-care group received 
a CRP test during the first 4 weeks of follow-up.
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Primary Outcomes
Of the 649 patients who were randomly assigned 
to a trial group, 537 (82.7%) contributed to the 
primary-outcome analysis of antibiotic use and 
563 (86.7%) contributed to the primary-outcome 
analysis of the total score on the Clinical COPD 
Questionnaire. Fewer patients in the CRP-guided 
group reported antibiotic use than in the usual-
care group (150 of 263 patients [57.0%] vs. 212 of 
274 patients [77.4%]; adjusted odds ratio, 0.31; 
95% confidence interval [CI], 0.20 to 0.47). The 
adjusted mean difference in the total score on the 
Clinical COPD Questionnaire at 2 weeks was −0.19 
points (two-sided 90% CI, −0.33 to −0.05) in favor 
of the CRP-guided group. The two-sided 90% con-
fidence interval for the complier average causal 
effect analysis ranged from −0.34 to −0.07. The 
upper limit of the confidence interval for both 
analyses did not contain the prespecified nonin-
feriority margin of 0.3. Our findings were consis-
tent in prespecified sensitivity analyses (Tables S2 
through S9 and Fig. S2 in the Supplementary 
Appendix).
Differences in reported antibiotic use were only 
observed for the patients who had at last two of 
the Anthonisen criteria (Fig. 2). Other differential 
effects of the assigned interventions are described 
in Section 9 in the Supplementary Appendix.
Secondary Outcomes
The antibiotic prescribing decisions made by cli-
nicians at the initial consultation were ascertained 
for all but 1 patient, and antibiotic prescriptions 
issued over the first 4 weeks of follow-up were 
ascertained for 96.9% of the patients. A lower 
percentage of patients in the CRP-guided group 
than in the usual-care group received antibiotic 
prescriptions at the initial consultation (47.7% vs. 
69.7%, for a difference of 22.0 percentage points; 
adjusted odds ratio, 0.31; 95% CI, 0.21 to 0.45). A 
total of 158 antibiotic prescriptions were issued 
to the patients in the CRP-guided group, and 234 
were issued to those in the usual-care group; 
12 patients (3 in the CRP-guided group and 9 in 
the usual-care group) were issued 2 prescriptions. 
The majority of prescriptions were for 7 days (138 
patients [87.3%] in the CRP-guided group and 185 
[79.1%] in the usual-care group). The prescribed 
antibiotics are listed in Table S10 in the Supple-
mentary Appendix.
At the initial consultation, antibiotics were pre-
scribed in the CRP-guided group for 79 of 241 
Figure 1. Screening, Randomization, and Follow-up.
The number of patients who were assessed for eligibility was estimated 
from screening log data obtained from 9 of 86 general medical practices 
that returned reliable screening log data (i.e., data that were regularly re-
turned and consistently included details of the number of patients who 
were approached in addition to the number of those who were recruited). 
From these 9 practices, 208 patients were approached (a mean number of 
23 patients approached per practice), which resulted in 1988 patients po-
tentially assessed for eligibility (208/9 × 86); 138 were eligible (66.3%), 
which resulted in 1319 patients potentially eligible (138/9 × 86); and 109 
(79.0%) were recruited. The main reasons for ineligibility were recent or 
current use of antibiotics (28 of 70 patients) or previous participation in 
the PACE study33 (13 of 70 patients). The main reasons for eligible patients 
not being recruited were patient’s decision to decline (18 of 29 patients) or 
lack of clinical time to recruit (9 of 29 patients). The recruited patients were 
randomly assigned to receive usual care guided by C-reactive protein (CRP) 
point-of-care testing (CRP-guided group) or usual care alone (usual-care 
group).
1319 Were eligible
1988 Patients were assessed for eligibility
4 Were excluded
3 Withdrew consent
1 Underwent randomization
in error and data were
destroyed
653 Underwent randomization
325 Were assigned to the CRP-guided
group
317 Received CRP point-of-care
testing
8 Did not receive intervention
owing to mechanical error
324 Were assigned to the usual-care
group
321 Did not receive CRP point-of-care
testing
3 Received CRP point-of-care
testing during the 4 wk after
randomization
263 Were included in the analysis of
 antibiotic use
281 Were included in the analysis of
the total score on the Clinical 
COPD Questionnaire
274 Were included in the analysis of
antibiotic use
282 Were included in the analysis of
the total score on the Clinical 
COPD Questionnaire
282 Had available data at wk 1
290 Had available data at wk 2
282 Had available data at wk 4
305 Had available data from the
medical record review at 6 mo
231 Had available data from the mailed
questionnaires at 6 mo
285 Had available data at wk 1
285 Had available data at wk 2
283 Had available data at wk 4
304 Had available data from the
medical record review at 6 mo
219 Had available data from the mailed
questionnaires at 6 mo
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Characteristic
CRP-Guided Group 
(N = 325)
Usual-Care Group 
(N = 324)
All Patients 
(N = 649)
Age — yr
Mean 67.8±9.53 68.3±9.31 68.1±9.42
Range 41–90 40–92 40–92
Sex — no. (%)
Male 162 (49.8) 173 (53.4) 335 (51.6)
Female 163 (50.2) 151 (46.6) 314 (48.4)
No. of days with symptoms before consultation
Mean 6.8±5.2 7.1±5.06 6.9±5.13
Range 1–28 1–21 1–28
Total score on the Clinical COPD 
Questionnaire†
Mean 3.2±1.16 3.3±1.11 3.3±1.14
Range 0.3–6.0 0.7–5.8 0.3–6.0
FEV1:FVC ratio‡
Mean 0.6±0.12 0.6±0.13 0.6±0.13
Range 0.30–0.85 0.23–0.85 0.23–0.85
Percentage of predicted FEV1§
Mean 59.2±19.33 60.4±20.73 59.8±20.04
Range 9.9–125.4 11.4–150.4 9.9–150.4
Coexisting illness — no./total no. (%)
Heart failure 16/325 (4.9) 15/324 (4.6) 31/649 (4.8)
Coronary heart disease 55/325 (16.9) 59/324 (18.2) 114/649 (17.6)
Diabetes 50/325 (15.4) 54/324 (16.7) 104/649 (16.0)
Chronic kidney disease 27/325 (8.3) 32/324 (9.9) 59/649 (9.1)
Hypertension 124/325 (38.2) 143/324 (44.1) 267/649 (41.1)
Other chronic disease 85/298 (28.5) 70/291 (24.1) 155/589 (26.3)
Smoking status — no./total no. (%)
Nonsmoker 20/281 (7.1) 22/279 (7.9) 42/560 (7.5)
Former smoker 165/281 (58.7) 163/279 (58.4) 328/560 (58.6)
Current smoker 96/281 (34.2) 94/279 (33.7) 190/560 (33.9)
Severity of COPD — no./total no. (%)¶
Mild, GOLD stage I 18/172 (10.5) 20/180 (11.1) 38/352 (10.8)
Moderate, GOLD stage II 93/172 (54.1) 100/180 (55.6) 193/352 (54.8)
Severe, GOLD stage III 52/172 (30.2) 47/180 (26.1) 99/352 (28.1)
Very severe, GOLD stage IV 9/172 (5.2) 13/180 (7.2) 22/352 (6.2)
No. of Anthonisen criteria present — no. (%)‖
1 76 (23.4) 81 (25.0) 157 (24.2)
2 100 (30.8) 98 (30.2) 198 (30.5)
3 149 (45.8) 145 (44.8) 294 (45.3)
Auscultation findings — no./total no. (%)
Crackles 158/325 (48.6) 162/324 (50.0) 320/649 (49.3)
Wheeze 171/325 (52.6) 167/324 (51.5) 338/649 (52.1)
Diminished vesicular sounds 71/325 (21.8) 82/322 (25.5) 153/647 (23.6)
Evidence of consolidation 11/324 (3.4) 8/323 (2.5) 19/647 (2.9)
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
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patients (32.8%) with a CRP value lower than 
20 mg per liter, for 32 of 38 (84.2%) with a CRP 
value between 20 and 40 mg per liter, and for 
36 of 38 (94.7%) with a CRP value higher than 
40 mg per liter. During the first 4 weeks of fol-
low-up, antibiotics were prescribed for 185 of 
313 patients (59.1%) in the CRP-guided group 
and for 252 of 316 patients (79.7%) in the usual-
care group (adjusted odds ratio, 0.30; 95% CI, 
0.20 to 0.46). We found no evidence of any be-
tween-group difference in the use of other treat-
ments for COPD (including oral glucocorticoids) 
during the first 4 weeks of follow-up (adjusted 
odds ratio, 0.79; 95% CI, 0.43 to 1.46). Addi-
tional details are provided in Tables S13 and S14 
in the Supplementary Appendix.
There was no evidence of clinically important 
between-group differences in the proportion of 
patients who had primary care consultations 
(i.e., consultation with a primary care clinician 
outside a hospital) or secondary care consultations 
(i.e., planned consultation with a specialist in a 
hospital) during 6 months of follow-up (adjusted 
odds ratio, 1.39; 95% CI, 0.46 to 4.15); in the pro-
portion of patients who received a diagnosis of 
pneumonia during the first 4 weeks of follow-up 
(adjusted odds ratio, 1.57; 95% CI, 0.28 to 8.84) 
and during 6 months of follow-up (adjusted odds 
ratio, 0.73; 95% CI, 0.29 to 1.82); and in health 
utility, with the scores averaged across the fol-
low-up time points (adjusted mean difference in 
score, 0.04; 95% CI, −0.02 to 0.10). With respect 
to general health status, patients in the CRP-
guided group reported a health status score that 
was more than 3 points higher than that reported 
by the patients in the usual-care group (adjusted 
mean difference, 3.12; 95% CI, 0.50 to 5.74). The 
adjusted mean differences in the scores on the 
CRQ-SAS were all small, ranging from −0.09 to 
0.15, with no confidence intervals containing val-
ues considered clinically important.41 There was no 
clinically important between-group difference in 
the proportion of patients who had sputum sam-
ples that contained potential pathogens at 1 month 
(adjusted odds ratio, 0.97; 95% CI, 0.63 to 1.50); 
in the proportion of patients who had sputum 
samples that contained antibiotic-resistant bacte-
ria (adjusted risk difference, 0.04; 95% CI, −0.03 
to 0.11); or in the proportion of patients who had 
throat swabs that contained antibiotic-resistant 
commensal and potentially pathogenic organisms. 
(Details are provided in Section 10 in the Supple-
mentary Appendix.)
Adverse Events
Two patients in the usual-care group died within 
the 4-week follow-up window, one from pneumo-
nia and one from respiratory failure; these deaths 
were not considered to be related to the trial in-
terventions or procedures, as determined by the 
trial investigators. During 6 months of follow-up, 
26 of 304 patients (8.6%) with available data in 
Characteristic
CRP-Guided Group 
(N = 325)
Usual-Care Group 
(N = 324)
All Patients 
(N = 649)
Previous treatment — no./total no. (%)
Received a prescription for oral antibiotics 
in the past 12 mo
205/304 (67.4) 198/302 (65.6) 403/606 (66.5)
Use of regular inhalers before recruitment 289/304 (95.1) 290/302 (96.0) 579/606 (95.5)
*  Plus–minus values are means ±SD. The recruited patients were randomly assigned to receive usual care guided by 
C-reactive protein (CRP) point-of-care testing (CRP-guided group) or usual care alone (usual-care group). There were 
no significant between-group differences in the demographic and clinical characteristics of the patients at baseline. 
Percentage may not total 100 because of rounding. COPD denotes chronic obstructive pulmonary disease.
†  Data on total score on the Clinical COPD Questionnaire were missing for 11 patients in the CRP-guided group and for 
8 patients in the usual-care group. The Clinical COPD Questionnaire is a 10-item scale with scores ranging from 0 (very 
good COPD-related health status) to 6 (extremely poor COPD-related health status).
‡  Data on the ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) were missing for 120 pa-
tients in the CRP-guided group and for 100 patients in the usual-care group.
§  Data on the percentage of predicted FEV1 were missing for 47 patients in the CRP-guided group and for 42 patients in 
the usual-care group.
¶  Severity of COPD was determined according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD).28
‖  The Anthonisen criteria include increased dyspnea, increased sputum volume, and increased sputum purulence.29
Table 1. (Continued.)
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the CRP-guided group had 35 hospitalizations, 
and 28 of 301 (9.3%) patients with available data 
in the usual-care group had 34 hospitalizations. 
During 6 months of follow-up, 9 of 305 patients 
(3.0%) in the CRP-guided group and 12 of 302 
patients (4.0%) in usual-care group received a di-
agnosis of pneumonia (adjusted odds ratio, 0.73; 
95% CI, 0.29 to 1.82). There was no evidence of 
a clinically important between-group difference 
in adverse effects from antibiotics (adjusted odds 
ratio, 0.79; 95% CI, 0.44 to 1.39) (Table S15 in the 
Supplementary Appendix).
Discussion
This randomized, controlled trial involving pri-
mary care patients presenting with an acute exac-
erbation of COPD showed that a management 
strategy with CRP point-of-care testing resulted 
in a lower percentage of patients reporting anti-
biotic use during the first 4 weeks of follow-up 
than those who received usual care alone, with 
a between-group difference of 20.4 percentage 
points. We found that CRP point-of-care testing 
also resulted in a lower percentage of patients 
who received an antibiotic prescription for acute 
exacerbation of COPD at the initial consultation 
and during the subsequent 4 weeks. Between-
group differences in the scores on the Clinical 
COPD Questionnaire during follow-up were small-
er than the published minimal clinically impor-
tant difference of 0.4, which indicates that less 
antibiotic use and fewer prescriptions from cli-
nicians did not compromise patient-reported dis-
ease-specific quality of life. Health care–seeking 
behavior or measures of patient well-being at 
6 months did not differ meaningfully between 
the trial groups, nor did secondary clinical, micro-
biologic, disease-specific quality-of-life, or health 
care utilization outcomes with respect to primary 
and secondary care.
We chose to include patient-reported antibiotic 
use for acute exacerbation of COPD during the 
first 4 weeks of follow-up as a primary outcome, 
because the main effects of interest involved 
actual antibiotic use. Antibiotics can be obtained 
from hospitals, services during out-of-office hours, 
leftover supplies, or rescue packs. Delayed or 
back-up antibiotic prescribing is fairly common 
for acute exacerbations of COPD in the United 
Kingdom, and not all of these prescriptions are 
collected from pharmacies or actually used.42 We 
captured data regarding antibiotic prescribing, 
antibiotic use, and health care utilization to de-
termine whether fewer initial prescriptions might 
have increased subsequent consulting and antibi-
otic prescribing and found that it did not.
We did not attempt to control for testing (e.g., 
sham tests for the usual-care group).43 Awareness 
of receiving the point-of-care test may have con-
tributed to enhanced COPD-related health status; 
however, this real-world effect needed to be cap-
tured because it may affect health care–seeking 
behavior, which is critical to assessments of over-
all benefit. Among the patients in the CRP-guided 
group, we did not observe patient-driven recon-
sultation during follow-up, a finding that is in 
line with a previous trial involving patients with 
lower respiratory tract infections.44
Although strategies for CRP point-of-care test-
ing in primary care have been shown to reduce 
antibiotic prescribing for respiratory tract infec-
tions in general,45,46 a small minority of patients 
in the studies that were included in systematic 
reviews had acute exacerbations of COPD,47 and 
none reported effects on antibiotic use. A non-
randomized Spanish study showed that the rate 
of antibiotic overprescribing for acute exacerba-
tions of COPD was lower among primary care 
clinicians who received training in CRP testing 
than among those who did not.48 A meta-analysis 
that included eight hospital-based trials showed 
Figure 2. Differential Effect of the Interventions on the Use of Antibiotics 
during the First 4 Weeks.
Shown is the predicted probability of antibiotic use for acute exacerbations 
of COPD during the first 4 weeks according to the number of Anthonisen 
criteria present. The Anthonisen criteria include increased dyspnea, in-
creased sputum volume, and increased sputum purulence. I bars denote 
95% confidence intervals.29
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evidence of a lower rate of antibiotic prescrip-
tions for acute exacerbations of COPD with pro-
calcitonin testing, without an effect on treatment 
failure, duration of hospitalization, exacerbation 
recurrence, or mortality; however, the trials that 
were included in the meta-analysis were typically 
small, and the quality of the evidence was con-
sidered to be low to moderate.49
The evidence from our trial suggests that 
CRP-guided antibiotic prescribing for COPD ex-
acerbations in primary care clinics may reduce 
patient-reported use of antibiotics and the pre-
scribing of antibiotics by clinicians.
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